Understanding trends in inpatient surgical volume: vascular interventions, 1980-2000

Anderson, Patrice; Gelijns, Annetine C.; Moskowitz, Alan J.; Arons, Ray; Gupta, Lopa; Weinberg, Alan; Faries, Peter L.; Nowygrod, Roman; Kent, K. Craig

doi:10.1016/j.jvs.2004.02.039

Cited by 157 publications

(114 citation statements)

References 13 publications

(12 reference statements)

Supporting

Mentioning

108

Contrasting

Unclassified

Order By: Relevance

“…Consequently, the results were similar for the endpoints of AFS, limb salvage, overall survival, CV death and MALE. The outcomes of EVT have recently improved, and this method has become common as a result of technical developments and improvements in devices [11][12][13] . Providing general anesthesia is difficult in many CLI patients with severe CAD, HF or LV dysfunction, although the number of high-risk patients who receive EVT is likely to increase.…”

Section: Discussionmentioning

confidence: 99%

Beta-blocker Treatment Does Not Worsen Critical Limb Ischemia in Patients Receiving Endovascular Therapy

Soga

Iida

Takahara

et al. 2015

JAT

View full text Add to dashboard Cite

Aim: It has been reported that beta-blockers (BB) reduce cardiovascular events in patients with atherosclerotic disease. However, little is known about the efficacy of these drugs in patients with critical limb ischemia (CLI). We investigated whether beta-blocker therapy affects the clinical outcomes of CLI patients. Methods: Between March 2004 and December 2011, 1,873 consecutive CLI patients who received endovascular therapy (EVT) (394 BB-treated patients and 1,479 non-BB-treated patients) for de novo infrainguinal lesions were identified retrospectively. A propensity score analysis was used for risk adjustment in a multivariable analysis and one-to-one matching (BB: 305, non-BB 305). The primary endpoint was amputation-free survival (AFS), and the secondary endpoints were overall survival and the rates of limb salvage and freedom from major adverse limb events (MALE; including repeat reintervention, surgical conversion and major amputation). The mean follow-up period was 22 15 months. Results: In the propensity score-matched pair analysis, there were no significant differences in AFS between the patients treated with and without beta-blockers (58.8% vs. 58.5% at three years, logrank p 0.76). There were also no significant differences in the limb salvage rate (88.3% vs. 88.8 at three years, log-rank P 0.41), overall survival (63.0% vs. 62.4% at three years, log-rank P 0.70) and freedom from MALE (43.6% vs. 44.9% at three years, log-rank P 0.58) between the patients treated with and without beta-blockers. Conclusions

show abstract

Section: Discussionmentioning

confidence: 99%

Beta-blocker Treatment Does Not Worsen Critical Limb Ischemia in Patients Receiving Endovascular Therapy

Soga

Iida

Takahara

et al. 2015

JAT

View full text Add to dashboard Cite

show abstract

“…5 More recent data from the US National Hospital Discharge Survey reveal a 500-fold increase in catheter-based interventions, from 1980 to 2000, to Ͼ160 000 noncoronary endovascular revascularization procedures (58.3 of 100 000). 6 We believe that health status ought to be a benchmark in the evaluation of novel strategies and emerging technologies in the treatment of symptomatic PAD.…”

Section: Safley Et Al Peripheral Revascularization and Health Status 573mentioning

confidence: 99%

Quantifying Improvement in Symptoms, Functioning, and Quality of Life After Peripheral Endovascular Revascularization

et al. 2007

View full text Add to dashboard Cite

Background— Patients with peripheral arterial disease often undergo peripheral endovascular revascularization (PER) to alleviate symptoms. Despite the growth of PER, little information exists quantifying the health status benefits after the procedure. Methods and Results— From February 2001 to August 2004, 477 consecutive patients underwent PER for symptomatic peripheral arterial disease. Of these, 300 consented to participate in a longitudinal follow-up study of their health status. Health status was quantified with the disease-specific Peripheral Artery Questionnaire and the generic Short Form-12 and the EuroQol 5 Dimensions (EQ5D)questionnaire. Scores range from 0 to 100; higher scores represent fewer symptoms and better health status. The average age of the cohort was 68±11 years (mean±SD); 186 (62%) were male, 288 (96%) were white, and 118 (39%) were diabetic. Clinical follow-up was attained in 99% of patients; health status assessments were made in 86%. Mean Peripheral Artery Questionnaire summary scores improved significantly after revascularization from 31±19 to 62±27 at 1 year ( P <0.0001). Generic health status scores also improved significantly ( P <0.001 for all). Despite a technically successful procedure in 98% of patients, 21% of patients did not achieve the minimal clinically important improvement of an 8-point change in Peripheral Artery Questionnaire Summary score after PER (35±19 at baseline versus 31±16 at 1 year; P =0.09). Conclusions— For most patients, significant and sustained improvements in symptoms, functioning, and quality of life occur after PER. Identifying and counseling patients less likely to benefit from PER is an important future research direction.

show abstract

“…Advances in techniques and devices have improved the outcomes and promoted the use of EVT [23][24][25] . the dose made based on the drug tolerability.…”

Section: Discussionmentioning

confidence: 99%

Clinical Impact of Bisoprolol Versus Carvedilol in Patients Undergoing Femoropopliteal Stenting

Soga

Iida

Suzuki

et al. 2014

JAT

View full text Add to dashboard Cite

Understanding trends in inpatient surgical volume: vascular interventions, 1980-2000

Cited by 157 publications

References 13 publications

Beta-blocker Treatment Does Not Worsen Critical Limb Ischemia in Patients Receiving Endovascular Therapy

Beta-blocker Treatment Does Not Worsen Critical Limb Ischemia in Patients Receiving Endovascular Therapy

Quantifying Improvement in Symptoms, Functioning, and Quality of Life After Peripheral Endovascular Revascularization

Clinical Impact of Bisoprolol Versus Carvedilol in Patients Undergoing Femoropopliteal Stenting

Contact Info

Product

Resources

About